TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02181192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Instant Radiotherapy according to guidelines
Description: Instant Radiotherapy according to guidelines

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy after achievement of PSA marginal value
Description: Radiotherapy after achievement of PSA marginal value
Study: NCT03358485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aolanti Weikang tablets
Description: Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05291364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
Study: NCT00543049

Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year

Intervention type: DRUG
Group type: OTHER
Intervention: SUNITINIB
Description: Sunitinib, oral, 37,5 mg once daily continuously, up to one year
Study: NCT02568202

Intervention type: OTHER
Intervention: No treatment given
Description: This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment.
Study: NCT03536520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT00984334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone SR 5 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone SR 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone SR 20mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone SR 2.5 mg capsules
Study: NCT02920645

Intervention type: OTHER
Intervention: AVM-related ICH
Study: NCT00554905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE first, then RFA within 2 weeks
Study: NCT02781233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Progressive resistance training program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal daily activities
Description: Usual daily activities
Study: NCT02259959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single rising doses of BI 1744 CL, solution for oral inhalation
Study: NCT04604353

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score
Description: Risk description to patient based on PRS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Calcium Score
Description: Risk description to patient based on CCS
Study: NCT01945034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical IBU twice daily
Description: Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo twice daily
Description: Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical IBU three times daily
Description: Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times daily
Description: Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
Study: NCT04941014

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Physical Activity
Description: The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Physical Activity
Description: The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vigourous Physical Activity
Description: The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
Study: NCT00937859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120
Description: SER120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02259959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium, fixed dose, solution for oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05890235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ningmitai Capsule
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai Capsule
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Study: NCT01489306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 10 day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 10 day period
Study: NCT02325739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.
Study: NCT01167816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
Study: NCT02325739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.
Study: NCT02099656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticposteroids (ICS)
Description: Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticposteroids (ICS)
Description: Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
Study: NCT02325739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
Study: NCT03296592

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI with DBSI technology
Description: The MRI will be done with diffusion basis spectrum imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI with DBSI technology
Description: The MRI will be done with diffusion basis spectrum imaging
Study: NCT03068429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride
Description: first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
Study: NCT02665858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OCT Imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OCT Imaging
Study: NCT01713374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mental stress
Description: Subjects will be asked to perform complex mathematic operations at a very fast pace

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: control visit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myogenic activation
Description: A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
Study: NCT02099656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Asthma Controller Medication
Description: Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Second Asthma Controller Medication
Description: Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
Study: NCT01489163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
Study: NCT04362722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2 +L19TNF
Description: Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
Study: NCT01025921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colistin (Tadim)
Description: 500.000 units of inhaled colistin three times daily for 10 days
Study: NCT01713374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressure test
Description: A hand will be placed in ice-cold water.
Study: NCT05208398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 5 mg twice daily, on top of standards of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
Study: NCT00739830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate tablets OR megestrol acetate
Description: oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
Study: NCT01678586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: In true acupuncture the needles penetrate the skin.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: In sham acupuncture the needles do not penetrate the skin.
Study: NCT01092247

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional support with Standard diet
Description: Nutritional support with Standard diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention with the Ketogenic diet
Description: Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
Study: NCT02513524

Intervention type: PROCEDURE
Intervention: Direct Observed Therapy test
Description: There is one group only, all of whom will undergo direct observed therapy testing
Study: NCT02537418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Study: NCT01025921

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inhaled normal saline
Description: inhalation of 2,5cc Normal Saline via nebulisation
Study: NCT05280522

Intervention type: OTHER
Intervention: Volitional Contractions (VOL)
Description: Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.

Intervention type: DEVICE
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.

Intervention type: DEVICE
Intervention: Noxious Electrical Stimulation (NXES)
Description: The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
Study: NCT03896971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of thrombopoietin mimetic and cyclosporin A
Description: This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
Study: NCT03746132

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EPIFLO
Description: EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
Study: NCT02699294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual pressure release
Description: Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
Study: NCT02892331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training (MOD-INT)
Description: Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
Study: NCT00791791

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standardized pain stimulus
Description: a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standardized pain stimulus
Description: a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
Study: NCT02892331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity exercise training (HI-INT)
Description: Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
Study: NCT03858387

Intervention type: DRUG
Intervention: Meropenem
Description: This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration.

Intervention type: DRUG
Intervention: Imipenem
Description: This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration.
Study: NCT03343769

Intervention type: OTHER
Intervention: BERG scale
Description: Complete the BERG balance scale

Intervention type: OTHER
Intervention: BERG scale
Description: Complete the BERG balance scale

Intervention type: OTHER
Intervention: Functional tests
Description: timed up and go, Mini motor test, retropulsion test

Intervention type: OTHER
Intervention: Functional tests
Description: timed up and go, Mini motor test, retropulsion test

Intervention type: OTHER
Intervention: Measurement of balance on a force platform
Description: 4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)

Intervention type: OTHER
Intervention: Measurement of balance on a force platform
Description: 4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)

Intervention type: OTHER
Intervention: Measurement of maximal moment of the plantar flexor and dorsiflexor muscles
Description: 5-second repetitions